451 related articles for article (PubMed ID: 10697624)
1. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
Messing EM; Manola J; Wilding G; Propert K; Fleischmann J; Crawford ED; Pontes JE; Hahn R; Trump D;
J Clin Oncol; 2003 Apr; 21(7):1214-22. PubMed ID: 12663707
[TBL] [Abstract][Full Text] [Related]
5. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant immunotherapy in renal cell carcinoma--comparison of interferon alpha treatment with an untreated control.
Basting R; Corvin S; Händel D; Hinke A; Schmidt D
Anticancer Res; 1999; 19(2C):1545-8. PubMed ID: 10365142
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
8. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
9. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
10. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
11. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
Taguchi S; Buti S; Fukuhara H; Otsuka M; Bersanelli M; Morikawa T; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
PLoS One; 2017; 12(2):e0172341. PubMed ID: 28241027
[TBL] [Abstract][Full Text] [Related]
12. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
[TBL] [Abstract][Full Text] [Related]
13. [Interferon and vinblastine in presumably operable metastases of renal carcinoma].
Pizzocaro G; Piva L; Faustini M; Mangiarotti B; Nicolai N; Salvioni R; Milani A; Zanoni F
Arch Ital Urol Androl; 1993 Apr; 65(2):177-80. PubMed ID: 8330064
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
15. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
Hernberg M; Muhonen T; Pyrhönen S
Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
[TBL] [Abstract][Full Text] [Related]
16. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
[TBL] [Abstract][Full Text] [Related]
17. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
18. Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ.
Shinohara N; Abe T; Sazawa A; Maruyama S; Shindo J; Sato S; Suzuki S; Nonomura K
Jpn J Clin Oncol; 2012 Feb; 42(2):113-9. PubMed ID: 22131341
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant interferon alpha therapy in renal cell carcinoma (RCC): prognostic value of DNA cytophotometry.
Basting R; Corvin S; Händel D; Hinke A; Schmidt D
Anticancer Res; 1999; 19(2C):1493-5. PubMed ID: 10365130
[TBL] [Abstract][Full Text] [Related]
20. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
